Research
TB-500 is sold on the back of thymosin beta-4 research — a different molecule with real but early human trials in wounds and eye disease. We untangle which studies are about what, and what that means for the fragment people actually buy.
PT-141 (bremelanotide) is FDA-approved as Vyleesi for low sexual desire in premenopausal women, with modest benefits and a lot of nausea. Its use in men — the way it is mostly marketed online — was abandoned in development. Here is what the trials actually showed.
Copper peptide GHK-Cu has decades of laboratory work, small human trials for topical skin use, and a growing injectable market with no human data. We grade each claim — skin, hair, wounds, 'gene resetting' — separately.
Oral collagen peptides are the rare non-drug peptide product with multiple randomised trials. The effects on skin hydration, activity-related joint pain and (with training) lean mass are real but small, and most trials are industry-funded. Here is what the studies show and where the gaps are.
The regulatory status of a peptide is a fact about a decision, not a verdict on the evidence. This guide explains the four categories, what compounding rules changed in 2023–2025, and where every peptide we cover currently sits.
Most misleading peptide claims cite real studies. This guide shows how to tell a rat model from a human trial, a mechanism from an outcome, and a case report from evidence — with worked examples from BPC-157, growth hormone secretagogues and collagen research.
Peptides are short chains of amino acids that range from approved blockbuster drugs to unregulated 'research chemicals'. Here is what the word actually covers, how peptides differ from proteins and small-molecule drugs, and why the category tells you nothing about evidence.
